Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin.
Rimantadine, ribavirin, and 6-mercapto-9-(tetrahydro-2-furyl)purine, administered intraperitoneally every 8 h for 7 days starting minutes after virus challenge, had no effect on survival and mean survival time of BALB/c mice inoculated intracranially with dengue virus type 2. In contrast, intraperitoneal treatment with ribavirin 2',3',5'-triacetate, a lipophilic analog of ribavirin, effected significant increases in both mean survival time and survival rate, suggesting that ribavirin 2',3',5'-triacetate may be superior to rabavirin for treatment of viral diseases of the brain.
D000218:Adamantane / Q000031:analogs & derivatives*; D000818:Animals; D001927:Brain Diseases / Q000188:drug therapy*; D003715:Dengue / Q000188:drug therapy*; D005260:Female; D015122:Mercaptopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D012254:Ribavirin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*; D012299:Rimantadine / Q000627:therapeutic use*
C020397:6-mercapto-9-(tetrahydro-2-furyl)purine; D012263:Ribonucleosides; D012299:Rimantadine; C038935:ribavirin 2',3',5'-triacetate; D012254:Ribavirin; D015122:Mercaptopurine; D000218:Adamantane